# To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines.

> **NCT04944953** · PHASE1 · COMPLETED · sponsor: **Hugel** · enrollment: 38 (actual)

## Conditions studied

- Glabellar Lines

## Interventions

- **DRUG:** Botulinum Toxin Type A Injection [Botox]
- **DRUG:** Botulinum toxin type A injection [HG-102]

## Key facts

- **NCT ID:** NCT04944953
- **Lead sponsor:** Hugel
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-11
- **Primary completion:** 2021-09-02
- **Final completion:** 2021-12-16
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04944953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04944953, "To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04944953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*